These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28961737)

  • 1. Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.
    Dorlo TPC; Kip AE; Younis BM; Ellis SJ; Alves F; Beijnen JH; Njenga S; Kirigi G; Hailu A; Olobo J; Musa AM; Balasegaram M; Wasunna M; Karlsson MO; Khalil EAG
    J Antimicrob Chemother; 2017 Nov; 72(11):3131-3140. PubMed ID: 28961737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.
    Mbui J; Olobo J; Omollo R; Solomos A; Kip AE; Kirigi G; Sagaki P; Kimutai R; Were L; Omollo T; Egondi TW; Wasunna M; Alvar J; Dorlo TPC; Alves F
    Clin Infect Dis; 2019 Apr; 68(9):1530-1538. PubMed ID: 30188978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmania blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic model.
    Verrest L; Monnerat S; Musa AM; Mbui J; Khalil EAG; Olobo J; Wasunna M; Chu WY; Huitema ADR; Schallig HDFH; Alves F; Dorlo TPC
    PLoS Negl Trop Dis; 2024 Apr; 18(4):e0012078. PubMed ID: 38640118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
    Wasunna M; Njenga S; Balasegaram M; Alexander N; Omollo R; Edwards T; Dorlo TP; Musa B; Ali MH; Elamin MY; Kirigi G; Juma R; Kip AE; Schoone GJ; Hailu A; Olobo J; Ellis S; Kimutai R; Wells S; Khalil EA; Strub Wourgaft N; Alves F; Musa A
    PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004880. PubMed ID: 27627654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.
    Verrest L; Roseboom IC; Wasunna M; Mbui J; Njenga S; Musa AM; Olobo J; Mohammed R; Ritmeijer K; Chu WY; Huitema ADR; Solomos A; Alves F; Dorlo TPC
    J Antimicrob Chemother; 2023 Nov; 78(11):2702-2714. PubMed ID: 37726401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa.
    Palić S; Kip AE; Beijnen JH; Mbui J; Musa A; Solomos A; Wasunna M; Olobo J; Alves F; Dorlo TPC
    J Antimicrob Chemother; 2020 Nov; 75(11):3260-3268. PubMed ID: 32780098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.
    Dorlo TP; Huitema AD; Beijnen JH; de Vries PJ
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3864-72. PubMed ID: 22585212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure.
    Dorlo TP; Rijal S; Ostyn B; de Vries PJ; Singh R; Bhattarai N; Uranw S; Dujardin JC; Boelaert M; Beijnen JH; Huitema AD
    J Infect Dis; 2014 Jul; 210(1):146-53. PubMed ID: 24443541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia.
    Palić S; Chu WY; Sundar S; Mondal D; Das P; Pandey K; Raja S; Rijal S; Roseboom IC; Hamadeh A; Malik PRV; Beijnen JH; Huitema ADR; Sjögren E; Alves F; Dorlo TPC
    J Antimicrob Chemother; 2024 Jul; 79(7):1547-1554. PubMed ID: 38727613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis.
    Voak AA; Harris A; Coteron-Lopez JM; Angulo-Barturen I; Ferrer-Bazaga S; Croft SL; Seifert K
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009013. PubMed ID: 33651812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.
    Ostyn B; Hasker E; Dorlo TP; Rijal S; Sundar S; Dujardin JC; Boelaert M
    PLoS One; 2014; 9(6):e100220. PubMed ID: 24941345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
    Marques N; Sá R; Coelho F; Oliveira J; Saraiva Da Cunha J; Meliço-Silvestre A
    Scand J Infect Dis; 2008; 40(6-7):523-6. PubMed ID: 18584541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome
    Goswami RP; Rahman M; Das S; Tripathi SK; Goswami RP
    Am J Trop Med Hyg; 2020 Jul; 103(1):308-314. PubMed ID: 32394874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miltefosine to treat leishmaniasis.
    Berman J
    Expert Opin Pharmacother; 2005 Jul; 6(8):1381-8. PubMed ID: 16013987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Miltefosine: a new remedy for leishmaniasis].
    Dorlo TP; Eggelte TA; Beijnen JH; de Vries PJ
    Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2697-701. PubMed ID: 17194005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.
    Dorlo TP; Balasegaram M; Lima MA; de Vries PJ; Beijnen JH; Huitema AD
    J Antimicrob Chemother; 2012 Aug; 67(8):1996-2004. PubMed ID: 22577099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral miltefosine treatment in children with visceral leishmaniasis: a brief review.
    Palumbo E
    Braz J Infect Dis; 2008 Feb; 12(1):2-4. PubMed ID: 18553005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.
    Kip AE; Rosing H; Hillebrand MJ; Blesson S; Mengesha B; Diro E; Hailu A; Schellens JH; Beijnen JH; Dorlo TP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2081-9. PubMed ID: 26787691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
    Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
    Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.